JAMA & ARCHIVES
Arch Fam Med
SEARCH
GO TO ADVANCED SEARCH
HOME  PAST ISSUES  TOPIC COLLECTIONS  CME  PHYSICIAN JOBS  CONTACT US  HELP
Institution: STANFORD Univ Med Center  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 9 No. 8, August 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (6)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Women's Health
 •Women's Health, Other
 •Alert me on articles by topic

Cost-effectiveness of the Conventional Papanicolaou Test With a New Adjunct to Cytological Screening for Squamous Cell Carcinoma of the Uterine Cervix and Its Precursors

Lynn A. Taylor, MPA; Sonja V. Sorensen, MPH; Nancy F. Ray, MS; Michael T. Halpern, MD, PhD, MPH; Diane M. Harper, MD, MPH

Arch Fam Med. 2000;9:713-721.

Objective  To estimate costs and outcomes of conventional annual Papanicolaou (Pap) test screening compared with biennial Pap test plus speculoscopy (PPS) screening for cervical neoplasms.

Design  A Markov model compared cost-effectiveness and outcomes of annual Pap tests with biennial PPS. The model includes direct costs of screening, diagnostic testing, and treatment for squamous intraepitheial lesions and invasive cancers; indirect costs (eg, lost productivity because of cervical cancer); and newer management practices, including human papillomavirus DNA testing.

Patients  Women aged 18 to 64 years.

Intervention  Screening for cervical neoplasms with either annual Pap smear test or biennial PPS.

Main Outcome Measure  Marginal cost per life-year gained.

Results  The probability of women having squamous intraepithelial lesions, cervical cancer, or death from cervical cancer was lower among women undergoing PPS biennially. A total of 12 additional days of life per woman was gained with biennial PPS during the 47-year model period. Total average cumulative direct medical costs per patient were $1419 for biennial PPS compared with $1489 for annual Pap tests. Total costs, including direct medical costs and indirect costs, were $2185 for PPS compared with $3179 for Pap tests alone. Increased savings and patient outcomes were observed in high-risk populations.

Conclusion  Our simulations indicate that biennial screening with PPS is expected to provide cost savings for women older than 18 years compared with annual Pap test screening, especially for those in high-risk populations.


From MEDTAP International, Inc, Bethesda, Md (Mss Taylor, Sorensen, and Ray and Dr Halpern), and Dartmouth Medical School, Hanover, NH (Dr Harper). Ms Taylor is now with the Pharmaceutical Research and Manufacturers of America, Washington, DC. Ms Ray is now with the Medicare Payment Advisory Commission, Washington.


RELATED ARTICLES

Editor's Comment
Marjorie A. Bowman
Arch Fam Med. 2000;9(8):721.
FULL TEXT  

The Archives of Family Medicine Continuing Medical Education Program
Arch Fam Med. 2000;9(8):735.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chapter 15: Public Health Policy and Cost-Effectiveness Analysis
Goldie
J Natl Cancer Inst Monogr 2003;2003:102-110.
ABSTRACT | FULL TEXT  




HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.